Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Abstract: Methods, systems, and devices for reference voltage adjustment for word line groups are described. In some examples, one or more components of a memory system may determine a duration that data has been stored to one or more memory cells. Based on the duration, a voltage value of one or more reference voltages may be adjusted accordingly. For example, a voltage value of one or more reference voltages may be adjusted based on the duration. Moreover, the reference voltage values may be adjusted differently in response to the memory cells having stored data for a relatively longer duration, as opposed to memory cells that have stored data for a relatively shorter duration. The adjusted reference voltages may be used during a subsequent read operation. The voltage value of the one or more reference voltages may be adjusted on a word-line group by word-line group basis.

Abstract: Aspects of the disclosure relate to methods for analyzing compositions comprising RNA species with unique nucleotide sequences for identification and/or ratio determination of RNAs. The disclosure is based, in part, on methods of cleaving identifying sequences from RNAs in a composition, and detecting the abundance of each identifying sequence to quantify the abundance of corresponding RNA species. Other aspects relate to methods for producing compositions comprising more than two RNA species, such as multivalent RNA compositions. The disclosure is based, in part, on methods of determining the proper amount of input DNA for in vitro transcription (IVT) reactions that will result in RNA being transcribed in a predetermined ratio. In some aspects, the disclosure relates to pharmaceutical compositions comprising multivalent RNA compositions produced by methods described, by the disclosure.

Abstract: An LED tube lamp includes a glass lamp tube, two end caps, an adhesive, an LED light strip, a plurality of LED light sources, a power supply, and a diffusion film. The glass lamp tube includes a main body region and two rear end regions. Each of the two end caps coupled to a respective rear end region by the adhesive. The LED light strip comprises a mounting region adhered to an inner circumferential surface of the glass lamp tube and a connecting region. The plurality of LED light sources are mounted on the mounting region. The power supply includes a circuit board separating from the LED light strip. The diffusion film is covering on an outer surface of the glass lamp tube. The connecting region, one of the rear end regions, the adhesive and one of the lateral wall are stacked sequentially in a radial direction of the glass lamp tube.

Abstract: A neutron capture therapy system may prevent deformation and damage of a material of a beam shaping assembly (20), thereby improving flux and quality of a neutron source. A boron neutron capture therapy system (100) includes a neutron generating device (10) and a beam shaping assembly (20), where the neutron generating device (10) includes an accelerator (11) and a target (T), a charged particle beam (P) generated by acceleration of the accelerator (11) interacts with the target (T) to generate neutrons, the neutrons form a neutron beam (N), the neutron beam (N) defines a main axis (X); the beam shaping assembly (20) includes a moderator (231), a reflector (232), and a radiation shield (233); and the beam shaping assembly (20) further includes a frame (21) accommodating the moderator (231).

Abstract: A neutron capture therapy system is provided, which may prevent a material of a beam shaping assembly from deformation and damaged, and improve the flux and quality of neutron sources. A boron neutron capture therapy system (100) includes a neutron generating device (10) and a beam shaping assembly (20). The neutron generating device (10) includes an accelerator (11) and a target (T). A charged particle beam (P) generated by acceleration of the accelerator (11) acts with the target (T) to generate neutrons. The neutrons form a neutron beam (N). The neutron beam (N) defines a main axis (X). The beam shaping assembly (20) includes a support part (21) and a main part (23) filled within the support part (21).

Abstract: An LED light bulb is provided. The LED light bulb includes a lamp housing, a bulb base, a stem, first and second conductive supports, a driving circuit, and a flexible LED filament. The flexible filament includes two conductive electrodes, a first LED section, a second LED section, and a conductive section. The first LED section is bent in a first space curved shape. The second LED section is bent in a second space curved shape. The conductive section includes a center point of the flexible LED filament. The flexible LED filament is bent in a third space curved shape comprising the first space curved shape and the second space curved shape.

Abstract: Disclosed are a pyrimidine-fused cyclic compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating cancer.

Abstract: An LED filament comprising a plurality of LED filament units, each of the plurality of LED filament units includes a LED chip with an upper surface and a lower surface opposite to the upper surface of the LED chip, and a light conversion layer comprising a top layer and a base layer, and the base layer comprises an upper surface and a lower surface opposite to the upper surface of the base layer, where the top layer with an upper surface and a lower surface opposite to the upper surface of the top layer is disposed on at least two sides of each of the LED chips, the lower surface of each of the LED chips is close to the upper surface of the base layer, and the upper surface of the top layer is away from each of the LED chips.

Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Abstract: An LED lighting device includes a seat, an optical assembly and a light source. The seat has a baseplate and a sidewall. A chamber is formed between the baseplate and the sidewall. The optical assembly completely covers a light-emitting side of the LED lighting device. The light source is disposed in the chamber of the seat and includes multiple LED arrays. Each LED array includes an LED chip. The optical assembly includes an optical unit. The optical unit includes multiple first optical members and multiple second optical members corresponding to the first optical members. The LED arrays correspond to the first optical members. Each first optical member possesses an effect of light diffusion resulting from its own material property. Each second optical member includes one or more sets of optical walls. Each set of optical walls surrounds one of the first optical members.

Abstract: Disclosed are a functional material for synchronously stabilizing multiple metals and a preparation method thereof, and a method for rehabilitating soil or wastewater contaminated by heavy metals (metalloids). The preparation method includes: mixing a ferrous salt, a ferric salt, a manganous salt, water, a dispersing material, and a phosphate to obtain a first mixture, and subjecting the first mixture to a first precipitation reaction to obtain a first reaction mixture containing the phosphate; adjusting a pH value of the first reaction mixture containing the phosphate to 10-12 by adding an alkali thereto to obtain a second mixture, subjecting the second mixture to a second precipitation reaction to obtain a second reaction mixture; and subjecting the second reaction mixture to a solid-liquid separation to obtain a solid, washing the solid, and drying to obtain the functional material for synchronously stabilizing multiple metals.

Abstract: Described are a number of aptamers that are specific to bind with lipoteichoic acid (LTA), and associated methods.

Abstract: The present disclosure discloses a kart and a frame thereof. The frame includes: a first frame including an outer sleeve and a first fixing piece arranged on the outer sleeve; a second frame including an inner sleeve defined with at least the two first perforations in an axial direction of the inner sleeve, the outer sleeve being fitted over the inner sleeve, one of the first frame and the second frame being a front frame and the other one being a rear frame; a second fixing piece including a rod section and a fitting section, the rod section being connected to a lower portion of the fitting section, the rod section protruding into any one of the first perforations of the inner sleeve from the first fixing piece, and the fitting section being fitted with the first fixing piece.

Abstract: This application relates to the field of lighting, and discloses an LED filament. The LED filament includes an LED chip unit, a light conversion layer, and an electrode. The light conversion layer covers the LED chip unit and part of the electrode, and a color of a light emitted by the LED filament after lighting is different from a color of the light conversion layer. This application has the characteristics of uniform light emission and good heat dissipation effect.

Abstract: A preparation method for a decellularized matrix biomaterial, which combines specific pretreatment, degreasing, disinfection, decellularization, ?-Gal antigen removal and sterilization, and reserves the integrity of bioactive components and structures in a material to the maximum extent while effectively removing an antigenic substance of an animal tissue, so that a decellularized matrix biomaterial having low immunogenicity and high biological activity is obtained. In addition, the decellularized matrix biomaterial prepared by the method effectively reduces immunogen components, has good biocompatibility and biological safety, is beneficial to cell adhesion, aggregation and proliferation on the surface, and can be used as a high-activity biological matrix material to be applied to skin soft tissue defect, gingival recession and periodontal soft tissue repair.